ASH 2023 | Investigating the cardiovascular toxicities associated with bispecific T-cell engagers
Daniel Addison, MD, The Ohio State University Wexner Medical Center, Columbus, OH, discusses a large-scale post-marketing surveillance study that aimed to identify safety signals and assess cardiovascular toxicity of the bispecific T-cell engagers (BiTEs) blinatumomab and teclistamab. The frequency of cardiovascular adverse events (CVAEs) was higher than that reported in clinical trials of BiTEs, and fatality rates associated with CVAEs were higher than with non-CVAEs. This study indicates the need for further investigation into the mechanisms by which BiTEs cause CVAEs and highlights the importance of more thorough surveillance strategies to reduce the incidence of these events. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
